Top Markets
Coin of the day
Catalent, Inc. Catalent, Inc.

Catalent, Inc.

CTLT
Pozycja w akcjach #1926
Catalent, Inc., operating globally through its various subsidiaries,... Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Cena akcji
$63.48
Ostatnia synchronizacja: 2024-12-17
Kapitalizacja rynkowa
$11.52B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Catalent, Inc. (CTLT)

Kategoria

Marża operacyjna dla Catalent, Inc. (CTLT)
Marża operacyjna na dzień August 2026 TTM: -17.10%
Według najnowszych raportów finansowych i ceny akcji Catalent, Inc., bieżąca marża operacyjna (TTM) wynosi -17.10%. Na koniec 2023 wynosiła -3.20%.
Historia marży operacyjnej dla Catalent, Inc. od 2011 do 2026
Marża operacyjna na koniec każdego roku
Rok Marża operacyjna Zmień
2026 (TTM) -17.10% 0.00%
2024 -17.10% 434.38%
2023 -3.20% -144.26%
2022 7.23% -18.31%
2021 8.85% 90.32%
2020 4.65% 89.80%
2019 2.45% -77.75%
2018 11.01% -2.39%
2017 11.28% -4.33%
2016 11.79% -16.97%
2015 14.20% 7.74%
2014 13.18% 16.12%
2013 11.35% -2.83%
2012 11.68% -3.87%
2011 12.15% 0.00%
Marża operacyjna dla podobnych firm lub konkurentów
Firma Marża operacyjna Różnica w marży operacyjnej Kraj
0.00% -
DE
0.00% -
DE
0.00% -
JP
0.00% -
CH
22.93% -101.34%
IN
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.